The sales are routine post-acquisition liquidity events, not a bearish signal. The CSO's sale was fully hedged by derivative exercises (zero net economic exposure change). Director grants are standard compensation. No follow-up action warranted — monitor next 10-Q for integration progress on Soleno's VYKAT XR.
Price Chart
Executive Summary
Two Neurocrine executives sold shares totaling $2.32M in the week following the close of the $2.9B Soleno acquisition. The CSO's sale of $1.71M was paired with a derivative exercise, while the Chief Corp. Affairs Officer sold $609K. Director grants on May 27 are non-cash compensation and carry no economic signal. The sales represent ~0.015% of market cap, well below the 0.1% materiality threshold, and are likely liquidity-driven following the acquisition close.
Key Financial Metrics
Key Facts
- CSO Onyia Jude sold 11,000 shares at $155.53 for $1.71M on May 27, paired with derivative exercises (11,000 shares at $0 and 11,000 shares at $84.74)
- Chief Corp. Affairs Officer Boyer sold 3,888 shares at $156.64 for $609K on May 26
- Total open-market sales: $2.32M, representing ~0.015% of NBIX's $15.7B market cap
- 11 directors received non-cash stock grants on May 27 totaling ~29,000 shares at $0 — routine compensation, no economic signal
- Sales occurred 9 days after the May 18 close of the $2.9B Soleno acquisition
Financial Impact
Total insider sales of $2.32M represent ~0.015% of market cap — immaterial relative to company size
Risk Factors
- Post-acquisition integration risk for Soleno's VYKAT XR (Prader-Willi syndrome) could pressure near-term earnings
- Additional $600M drawn on $1.0B credit facility increases leverage, though manageable for a $15.7B market cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780092662734 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $149.50 $139.49 | ▼ −6.70% | ▼ −9.26% | $143.18 (−4.23%) |
Jul 13, 2026 11w ago | Insider Cluster | $174.10 $170.88 | ▼ −1.85% | ▼ −1.06% | $143.18 (−17.76%) |
Jul 9, 2026 12w ago | Press Release | $177.11 $171.55 | ▼ −3.14% | ▼ −2.58% | $143.18 (−19.16%) |
Jun 9, 2026 16w ago | Insider Cluster | $160.86 $156.42 | ▼ −2.76% | ▼ −6.19% | $143.18 (−10.99%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 4, 2026 17w ago | Insider Cluster | $163.88 $159.76 | ▼ −2.51% | ▼ −3.08% | $143.18 (−12.63%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access